Jean-Baptiste Guillerme

Learn More
Lung and colorectal cancers are responsible for approximately 2 million deaths each year worldwide. Despite continual improvements, clinical management of these diseases remains challenging and development of novel therapies with increased efficacy is critical to address these major public health issues. Oncolytic viruses have shown promising results(More)
Antitumor virotherapy using oncolytic viruses (OV) is currently assessed in numerous clinical trials. 1 This therapeutic approach consists of the use of attenuated and/or genetically modified replication-competent virus to preferentially infect and kill tumor cells, with limited infection , if any, of healthy cells. Among the different oncolytic viruses,(More)
Antitumor virotherapy consists of the use of replication-competent viruses to infect and kill tumor cells preferentially, without damaging healthy cells. Vaccine-attenuated strains of measles virus (MV) are good candidates for this approach. Attenuated MV uses the CD46 molecule as a major entry receptor into cells. This molecule negatively regulates the(More)
Attenuated measles virus (MV) is currently being evaluated in clinical trials as an oncolytic therapeutic agent. Originally used for its lytic activity against tumor cells, it is now admitted that the effectiveness of MV also lies in its ability to initiate antitumor immune responses through the activation of dendritic cells (DCs). In this study, we(More)
  • 1